Cubist Submits CTA to Dutch Competent Authority and Ethics Committee to Initiate First-in-Human Study of CB-618

By: Benzinga
Cubist Pharmaceuticals (NASDAQ: CBST ) today announced that it submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.